Dr. Adam STOTEN, Deputy Head of Technology Transfer at ISIS Innovation Ltd, the technology transfer company of the University of Oxford will be sharing his experiences in the following panel:

“Scouting innovation: academia push and industry pull” on december 3rd and 4pm

Academia wants to push out knowledge and innovation on the one hand and the industry is looking to pull it in and bring it to market on the other hand. However simple this might seem, when putting it into practice there are many challenges to overcome. Let’s find out which are the new models that pharma and biotech are using in scouting the innovation and how are TTOs better packaging the offer in order to find more matches with the demand?

Dr. Adam STOTEN’s biography

Adam joined Isis in the role of Deputy Head of Technology Transfer in 2013, with specific responsibility for commercialisation of life/medical science technologies originating from Oxford research. Adam has worked for more than a decade in the pharma/biotech sector in commercial roles encompassing business development and licensing, new venture formation, product development, lobbying/advocacy and general management. Between 2010 and 2013 Adam worked for Emergent BioSolutions Inc as Deputy General Manager for the Oxford-Emergent Tuberculosis Consortium Ltd, a joint venture with the University of Oxford which conducted the first ever efficacy study of a new TB vaccine in infants. Adam first worked at Isis between 2005 and 2010, successfully managing a wide range of licensing deals and spin-outs spanning therapeutics, vaccines, diagnostics, research tools and software. Prior to 2005 he worked as Head of Research for a specialist pharma/biotech consultancy undertaking due diligence and market research projects. Adam has a 1st Class Honours degree in biology and a PhD in immunology from the University of Nottingham.

Contact us to take part in this panel

Check full program

Current Partnering, the leading publisher of deal term reports within the life sciences.

Designed to translate research into commercial success, Current Partnering provides an opportunity for the dissemination of the latest trends in partnering activity across the life sciences.

Current Partnering report titles cover all aspects of partnering best practice and deal terms, providing users with the information and insight required to optimise their partnering activities.

Their reports cover all aspects of partnering best practice. Recent titles include:

• Companion Diagnostics Partnering Terms and Agreements
• Biomarker Partnering Terms and Agreements
• Partnering Agreements in Diagnostics
• Co-promotion and Co-marketing Agreements in Pharma and Biotech
• Merger and Acquisition Agreements in Pharma and Biotech
• Product and Asset Purchase Agreements in Pharma, Biotech and Diagnostics
• Option and Evaluation Agreements in Pharma and Biotech
• Royalty Financing Agreements in Pharma, Biotech and Diagnostics
• Practical Guide to Finding Partners in Pharma and Biotech
• Partnering Agreements with Big Pharma

Further details for each report can be viewed online.

Check full list of Supporters

Thank you for visiting the french pavillion and meeting the BioFIT team.

We hope you all enjoyed your stay in San Diego city and had successfull meetings at the BIO Convention.

The special discount for BIO attendees still stands. Register by the end of this week and you will receive 50% off the regular fee for the 2nd attendee at BioFIT event.

Please register with the promotional code: BIODISCOUNT

Register NOW

Heading to San Diego next week for the BIO Convention? We too !

Don’t forget to come by the french pavilion #2917, Nutrition Health and Longevity Cluster booth to get your DISCOUNT COUPON to attend BioFIT 2014 next December 2nd and 3rd.

Schedule a meeting with us and learn more on BioFIT opportunities for presenting and speaking !

Maximize your visibility at the exhibition area or become a sponsor of the event.

Become a sponsor

Present your technology or services

Share a panel discussion with international experts

Exhibition fees

 

BioFIT preliminary program is now available !

Discover attendees profiles, the conference agenda, a  speakers list and BioFIT hosted events.

Download the program

The first Scientific Committee Meeting for IDEA Summit was held last Tuesday June 11th in Lille. Experts in the field discussed latest trends and research results in the field, highlighting hot issues that must be discussed during the Summit next December 2nd and 3rd.

On the menu:

• a Partnering Convention with academia, biotech, pharma, biobanks, incubators, clusters, investors, policy makers
• Conferences and round tables to explore hands-on approaches to private/public collaborations among which Stratified Medicine, Translational research, Research Agenda…

About IDEA Summit

IDEA Summit is the unique event dedicated to translational research on diabetes in Europe. Key decision makers from academia and industry, and other stakeholders attend the meeting.

About the Scientific Committee

Its role is to define and steer the content of the conference program and contribute to the recruitment of speakers.

Members:

• Philippe FROGUEL, Director of UMR CNRS 8199, Pasteur Institute of Lille (FR) and Professor and Chair of Genomics of Common Disease, Imperial College London (UK)
• Mark PEAKMAN, Professor of Clinical Immunology, King’s College London – Immunobiology (UK)

• Mark WALKER, Professor of Molecular Diabetic Medicine, University of Newcastle (UK)

• Stefano DEL PRATO, Professor of Endocrinology and Metabolism at the School of Medicine, Chief of the Section of Diabetes, University of Pisa (IT)
• Leif GROOP, MD, PhD, Professor, Head of Unit, Lund University (SE)
• Marc DONATH, Professor at Endocrinology, Diabetes and Metabolism, University Hospital Basel (CH)

Learn more on IDEA SUMMIT

Register now and enjoy our Early Bird fees

Check out BioFIT 2012 film commented by attendees.

Don’t miss the next edition next december !